2 Beaten-Down Stocks That Could Sink Even More in 2026

Sarepta Therapeutics faces material safety setbacks after two patients died from liver failure following its gene therapy Elevidys, prompting a boxed warning, restricted use in high‑risk populations and a greater than 80% share price decline last year; management now pegs full‑year 2025 revenue at $1.86 billion versus $1.9 billion in the prior year, and abandoned a separate pipeline candidate after related fatalities, leaving near‑term growth prospects weak despite early‑stage programs. Teladoc Health continues to struggle with stagnant revenue growth and accumulated net losses, with its BetterHelp mental‑health platform losing paying members and sales, acquisitions yet to move the needle, and international gains unlikely to offset domestic competitive pressures, all pointing to continued downside for the shares.

Analysis

Market structure: Safety-driven demand shock at Sarepta (SRPT down >80% last year) materially reduces pricing power for high-priced, single-administration gene therapies and shifts pricing leverage to payers and hospital systems (favoring UNH, CVS). Teladoc (TDOC) weakness signals commoditization of telehealth; incumbents with integrated ecosystems (insurers, EHR incumbents) gain share while standalone virtual-care pure-plays face margin compression. Volatility in both names lifts equity option IV; issuer-specific credit spreads for small-cap biotech may widen modestly, pushing risk‑off flows into Treasuries and large-cap defensives in the near term.

Risk assessment: Tail risks include FDA further restricting or withdrawing Elevidys (50–100% downside for SRPT in an extreme case), class-action/litigation fines, and manufacturing liabilities that could emerge within 3–12 months. For TDOC the tail is sustained member attrition leading to covenant stress or a need for dilutive capital—reasonable downside over 6–12 months if revenue growth remains <5% YoY. Hidden dependencies: payer reimbursement decisions and hospital adoption cycles (60–180 day decision windows) are the key second-order levers for recovery or further decline.

Trade implications: Size positions small (1–3% portfolio) and favor defined-risk option structures: for SRPT buy 3–6 month put spreads to capture further downside while limiting gamma risk; for TDOC initiate a 2% short stock position capped with 9-month calls (buy 1.5x hedge) or use put spreads. Rotate 3–9 month exposure from small-cap biotech and pure-play telehealth into UNH (2–3% long) and JNJ (2% long) to harvest defensive, cash-generative exposure and payer benefit from telehealth adoption.

Contrarian angles: The market may be overshooting liability risks—if Sarepta demonstrates a clear liver‑monitoring mitigation plan and FDA advisory outcomes are neutral, a >50% rebound is plausible within 3–6 months, so avoid naked shorts. Historical parallels: past biotech safety scares reversed sharply on credible mitigation/data; thus prefer capped-loss instruments. Watch for M&A interest in TDOC’s BetterHelp or platform assets as a potential upside catalyst that would materially alter short thesis.

Key Decisions for Investors

• Establish a capped short on SRPT: allocate 1–2% of portfolio to a 3–6 month put spread (buy near‑ATM put, sell a further OTM put ~50% width) sized to risk no more than 1% portfolio loss. Reassess at any FDA advisory/label change or if Elevidys prescriptions rebound >25% QoQ.
• Initiate a hedged short on TDOC: short 2% notional of TDOC equity and buy 1.5x notional of 9‑month calls as a hedge (cost-funded by selling near-term OTM calls if desired). Cover if BetterHelp paying members reverse trend to +5% QoQ or if company secures broad insurer reimbursement within 6 months.
• Pair trade: rotate 3–5% from SRPT/TDOC into large-cap healthcare defensives—go long UNH (2–3%) and JNJ (2%) for 3–9 months to capture payer/integration upside and lower beta cash flow. Trim if UNH or JNJ outperform peers by >15% in 60 days.
• Buy systemic insurance: purchase 3‑month 3–5% OTM puts on IBB (biotech ETF) sized to 0.5–1% portfolio as tail‑risk protection against sector‑wide regulatory shocks tied to safety events; expire or roll at 30‑day readouts or after major FDA decisions.